- AutorIn
- Hans-Josef Feistritzer
- Steffen Desch
- Anne Freund
- Janine Poess
- Uwe Zeymer
- Taoufik Ouarrak
- Steffen Schneider
- Suzanne de Waha-Thiele
- Georg Fuernau
- Ingo Eitel
- Marko Noc
- Janina Stepinska
- Kurt Huber
- Holger Thiele
- Titel
- Prognostic Impact of Active Mechanical Circulatory Support in Cardiogenic Shock Complicating Acute Myocardial Infarction, Results from the Culprit-Shock Trial
- Zitierfähige Url:
- https://nbn-resolving.org/urn:nbn:de:bsz:15-qucosa2-848016
- Quellenangabe
- Journal of Clinical Medicine
Erscheinungsjahr: 2020
Jahrgang: 9
Heft: 6
E-ISSN: 2077-0383
Artikelnummer: 1976 - Erstveröffentlichung
- 2020
- Abstract (EN)
- Objectives: To analyze the use and prognostic impact of active mechanical circulatory support (MCS) devices in a large prospective contemporary cohort of patients with cardiogenic shock (CS) complicating acute myocardial infarction (AMI). Background: Although increasingly used in clinical practice, data on the efficacy and safety of active MCS devices in patients with CS complicating AMI are limited. Methods: This is a predefined subanalysis of the CULPRIT-SHOCK randomized trial and prospective registry. Patients with CS, AMI and multivessel coronary artery disease were categorized in two groups: (1) use of at least one active MCS device vs. (2) no active MCS or use of intra-aortic balloon pump (IABP) only. The primary endpoint was a composite of all-cause death or renal replacement therapy at 30 days. Results: Two hundred of 1055 (19%) patients received at least one active MCS device (n = 112 Impella®; n = 95 extracorporeal membrane oxygenation (ECMO); n = 6 other devices). The primary endpoint occurred significantly more often in patients treated with active MCS devices compared with those without active MCS devices (142 of 197, 72% vs. 374 of 827, 45%; p < 0.001). All-cause mortality and bleeding rates were significantly higher in the active MCS group (all p < 0.001). After multivariable adjustment, the use of active MCS was significantly associated with the primary endpoint (odds ratio (OR) 4.0, 95% confidence interval (CI) 2.7–5.9; p < 0.001). Conclusions: In the CULPRIT-SHOCK trial, active MCS devices were used in approximately one fifth of patients. Patients treated with active MCS devices showed worse outcome at 30 days and 1 year.
- Andere Ausgabe
- Link zur Erstveröffentlichung
Link: https://doi.org/10.3390/jcm9061976 - Freie Schlagwörter (EN)
- cardiogenic shock; acute myocardial infarction; mechanical circulatory support; prognosis
- Klassifikation (DDC)
- 610
- Verlag
- MDPI, Basel
- Version / Begutachtungsstatus
- publizierte Version / Verlagsversion
- URN Qucosa
- urn:nbn:de:bsz:15-qucosa2-848016
- Veröffentlichungsdatum Qucosa
- 20.04.2023
- Dokumenttyp
- Artikel
- Sprache des Dokumentes
- Englisch
- Lizenz / Rechtehinweis
CC BY 4.0